Evidence map›Paper›PMID 41925873›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Pre-treatment audiological and vestibular assessment in adults starting platinum-based chemotherapy.

Heleen Van Der Biest, Sarah Verhulst, Hannah Keppler, Leen Maes, Frederic Acke, Eline Naert, Sylvie Rottey, Ingeborg Dhooge

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Heleen Van Der BiestDepartment of Head and Skin, Ghent University, Ghent, Belgium. heleen.vanderbiest@ugent.be.ORCID http://orcid.org/0000-0001-7174-3950
Sarah VerhulstDepartment of Information Technology - Hearing Technology @Waves, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0002-6498-7719
Hannah KepplerDepartment of Rehabilitation Sciences - Audiology, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0002-8684-9448
Leen MaesDepartment of Rehabilitation Sciences - Audiology, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0001-6090-5512
Frederic AckeDepartment of Head and Skin, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0001-6312-4260
Eline NaertDepartment of Medical Oncology, Ghent University Hospital, Ghent, Belgium.ORCID http://orcid.org/0000-0002-1508-7263
Sylvie RotteyDepartment of Medical Oncology, Ghent University Hospital, Ghent, Belgium.ORCID http://orcid.org/0000-0003-2060-3725
Ingeborg DhoogeDepartment of Head and Skin, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0002-5915-1079

Funding

Fonds voor Innovatie en Klinisch Onderzoek FIKO21/TYPE2/007
6 · The paper itself

Abstract

purposeTo evaluate the feasibility of incorporating both standard and novel audiological and vestibular assessments into routine oncology care. A secondary objective was to characterize audiovestibular status prior to platinum-based chemotherapy and identify potential risk factors for cochleotoxicity and vestibulotoxicity.

methodThis single-center, cross-sectional prospective study enrolled 110 adults scheduled for their first platinum-based chemotherapy cycle. All assessments were performed at one time point prior to treatment initiation. Pre-treatment assessments included tympanometry, pure-tone audiometry, speech audiometry in quiet and noise (SPIQ and SPIN), distortion product otoacoustic emissions (DPOAEs), auditory brainstem responses (ABRs), envelope following responses (EFRs), video head impulse testing (vHIT), and cervical vestibular evoked myogenic potentials (cVEMP).

resultsAll patients underwent tympanometry and pure-tone audiometry. A broader audiological test battery was completed in 96 patients (87.3%). At least one vestibular assessment was performed in 65 patients (59.1%). Completion of the protocol was limited by age, fatigue, or logistical constraints. Vestibular assessments were sometimes hindered by physical and time limitations. Before the start of chemotherapy, hearing loss was present in 44.5% of patients (30.9% bilateral, 13.6% unilateral), while 9.1% reported tinnitus and 34.5% reported difficulty understanding speech in noise. Speech audiometry (SPIQ and SPIN SRTs) revealed significant differences between age groups, with post-hoc analysis showing differences between the 34-57 group and the older groups. DPOAE amplitudes were significantly different across age groups at 1500 Hz, 2000 Hz, 3000 Hz, 4000 Hz, and 6000 Hz. EFR magnitudes, as well as ABR amplitudes and latencies, did not differ significantly between age groups. At baseline, three patients were diagnosed with benign paroxysmal positional vertigo (BPPV). vHIT revealed vestibulo-ocular reflex (VOR) gain deficits in three patients. cVEMP responses were absent bilaterally in three patients and unilaterally in one.

conclusionAudiological assessments were largely feasible, even in older adults, and revealed pre-existing audiovestibular deficits including high-frequency hearing loss and BPPV. Given risk factors such as advanced age, baseline hearing deficits, and planned type of platinum-based chemotherapy, this population is particularly vulnerable to cochleotoxicity. These findings support implementing a pre-treatment audiovestibular protocol that can serve as a baseline for subsequent longitudinal ototoxicity monitoring, with individualized adaptations to optimize feasibility and to support early detection of ototoxic changes and timely intervention during follow-up.

Indexed as

Antineoplastic AgentsAcoustic Impedance TestsAdultAgedAudiometry, Pure-ToneCross-Sectional StudiesEvoked Potentials, Auditory, Brain StemFeasibility StudiesFemaleHearing LossHumansMaleMiddle AgedOtotoxicityProspective StudiesRisk FactorsAntineoplastic AgentsAudiological and vestibular assessmentCochleotoxicityOtotoxicityPlatinum-based chemotherapyPre-treatment assessmentVestibulotoxicity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.